Peter Patriarca

ppatriarca@bcg-usa.com

Peter Patriarca

CV in Adobe

Contact

 

EDUCATION:

M.D. Tulane University School of Medicine (with highest honors), New Orleans, LA
B.S. University of Notre Dame (with honors), Notre Dame, IN

EXPERTISE

    • 30+ years of post-graduate experience, including 12 years as an infectious disease epidemiologist and 19 years in biologics development and regulation (at CBER/FDA [~9 yrs], industry [~4 yrs] and consulting [~6 yrs]).  Product experience primarily includes vaccines, adjuvants, and monoclonal antibodies.
    • Board certified pediatrician with additional training and experience in laboratory science, epidemiology, biostatistics, drug safety, and project management.
    • Principal investigator in epidemiologic research and large-scale vaccine efficacy studies.
    • Extensive international experience, including interactions with high-level personnel within WHO, government and non-governmental organizations.
    • Extensive vaccine policy experience, both in the U.S. and abroad.
    • World-renowned expert in influenza, poliomyelitis, measles, pertussis and other vaccine-preventable diseases with ~100 peer-reviewed journal articles, book chapters and books.

     

    INFLUENZA- AND INFLUENZA VACCINE-RELATED EXPERTISE

    • Lead Medical Epidemiologist assigned to the Influenza Branch, Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA
    • Principal Investigator in two influenza vaccine and therapeutics trials
    • Organizer and/or speaker for multiple scientific meetings and sessions on influenza and influenza vaccines; author or co-author of ~35 peer-review publications on influenza and influenza vaccines
    • Former Chairman of the Inter-Agency Working Group in Pandemic Preparedness in the United States
    • Supervisory responsibility for all influenza vaccine-related regulatory submissions while serving as Director of the Division of Viral Products, Center for Biologics Evaluation and Research (CBER)/FDA
    • Lead clinical reviewer for selected influenza-related INDs and BLAs
    • Chair of FDA/CBER's internal Cell Substrate Working Group
    • Frequent attendee and presenter at CDC's Advisory Committee on Immunization Practices (ACIP) and former FDA liaison member to the AAP's Committee on Infectious Diseases
    • Regulatory lead for the successful approval of FluMist® (Influenza Virus Vaccine Live, Intranasal) and transition to the new refrigerator-stable formulation (CAIV-T). Also served as Regulatory lead for 5 commercial manufacturing sites and 2 pilot plants, including FDA approval for MedImmune's new state-of-the-art manufacturing facility in Speke, U.K.
    • Member of MedImmune's strategic and operations committees, including Executive Management, Commercial Operations, Product Development, Product Safety, Labeling and Corporate Compliance Committees. Also served as regulatory lead for all mergers, acquisitions, in-licensing, out-licensing and other business development activities.
    • Extensive consulting experience with large and small developers of influenza vaccines, including novel investigational products, adjuvants, and routes of administration
    • Numerous due diligence assignments pertaining to investment or M & A decisions
    EXPERIENCE
    CURRENT POSITION
    May 2005 - present
    		  

    Senior Clinical Consultant, Biologics Consulting Group, Inc.
    Bethesda, MD.

    • Provides wide range of regulatory (strategic, CMC and clinical) advice to various clients in the drug industry, focusing primarily on vaccines and other biological products.
    • Specialties include regulatory strategy, product development strategy, clinical protocol design, regulatory submission preparation and review, and FDA and Advisory Committee meeting preparation.
    • Pro bono work:
      • Expert, Research and Development Working Group, Decade of Vaccines Collaboration (2011-present)
      • Member, Scientific Advisory Board, RSV Vaccine Development, PATH (2011-present)
      • Member, National Academy of Science’s (NAS) Biodefense Standing Committee for the U.S. Department of Defense (2008-2011)
      • Member, Institute of Medicine (IOM) Committee on Assessment of Future Scientific Needs for Live Variola Virus (2008-2009)
      • Member, Institute of Medicine (IOM) Committee on the Special Immunization Program for Laboratory Personnel Engaged in Research on Countermeasures for Select Agents (2009-2011)
      • Member, Task Force for Global Health Poliovirus Antivirals Steering Committee (2008-present)
       
    Aug. 2001 - Apr. 2005  

    Corporate Head and Vice President, World-wide Regulatory Affairs and Pharmacovigilance, MedImmune, Inc., Gaithersburg, MD.

    • Member of key strategic and operations committees, including Executive Management, Commercial Operations, Product Development, Product Safety, Labeling and Corporate Compliance Committees.
    • Strategic, operational and compliance responsibility for 5 licensed and 18 investigational products, including vaccines, monoclonal antibodies, plasma derivatives and small molecules.
    • Also provided regulatory support to 5 commercial manufacturing sites and 2 pilot plants. Department handled ~1000 regulatory submissions annually (US and foreign).
    • Built Department from a staff of 12 members to 45. Expanded each of three therapeutic areas (ID/Immunology, Oncology and Vaccines)
    • Created a Regulatory Operations Division (including submission publishing and electronic submissions capability)
    • Increased post-marketing drug safety surveillance capability (including installation of a new global safety database)
    • Established risk management and regulatory intelligence functions.
    • Maintained "hands on" skills by taking primary responsibility for writing and coordinating key submissions (including MedImmune's first IMPD and CTD) and participating (typically as lead) in all interactions with the FDA, including sponsor and Advisory Committee meetings, telecons and pharmacovigilance and BIOMO inspections
    • Provided support to QA for GMP inspections, including PAIs and biannual (Team Biologics) inspections.
    • Served as regulatory lead for all mergers, acquisitions, in-licensing, out-licensing and other due diligence activities.
       
    1995 - 2001  

    Deputy Director (1995-1997), Acting Director (1997) and Director (1997-2001), Division of Viral Products, Office of Vaccines Research and Review, CBER, FDA, Bethesda, MD.

    • Managed full-time staff of ~100 employees, including 60 senior scientists involved in basic and applied laboratory-based research in HIV and other retroviruses, hepatitis, arboviruses, herpesviruses, poxviruses, enteroviruses and respiratory viruses.
    • Directed Division activities related to the medical, public health, and regulatory aspects of viral vaccines, including licensed and investigational products.
    • Review portfolio consists of hundreds of active INDs and BLA supplements, Master Files, and 6 original BLA applications.
    • Responsible for secondary and tertiary review; quality and consistency of CMC and clinical reviews performed by subordinate staff; and primary review for selected INDs and BLAs.
    • Integral participant in licensing committee deliberations and senior management oversight and approval decisions.
    • Interacted extensively with industry during all phases of product development, including Advisory Committee Meetings, face-to-face meetings, and teleconferences and ad hoc consultations.
    • Participated in Guidance Document development and review, including ICH-related, combination vaccines, toxicology, reproductive toxicology, surrogate endpoints, and internal clinical review practices.
    • Chair of working group concerned with the development and regulation of novel cell substrates for the production of viral vaccines.
    • Chair of government-wide working group on influenza pandemic preparedness in the U.S., with primary focus on rapid development and deployment of vaccines and antiviral agents.
    • Member of the Poliomyelitis Eradication Certification Commission for the Western Pacific Region , World Health Organization (1996-2001).
    • FDA liaison representative to the American Academy of Pediatrics Committee on Infectious Diseases ("Redbook Committee")
       
    1994 - 1995  

    FDA Coordinator for the National Institute of Biologicals Project, India, CBER, FDA, Office of Medical and International Affairs, Office of the Director, Bethesda, MD.

    • In collaboration with other scientists within CBER and architects and engineers at the NIH, developed scientific, regulatory and laboratory training programs for the National Institute of Biologicals (NIB) Project, India, a $100+ million project sponsored by the U.S. and Japanese Governments.
    • The NIB is an independent agency established within the Ministry of Health and Family Welfare, New Delhi, that was responsible for quality control testing of all biological products.
    • Participated in optimal facility design, testing algorithms, and tech transfer of key in vitro and in vivo assays from the U.S. FDA.
    • Performed product and clinical reviews of selected biologics applications as assigned.
       
    1993  

    Associate Director for Vaccine Research, National Vaccine Program Office, DHHS, Office of the Assistant Secretary for Health, Rockville, MD.

    • Coordinated vaccine-related research activities (domestic and international) carried out by Federal Agencies
    • Coordinated activities related to vaccine safety; coordinated Federal roles in the distribution and use of vaccines in the U.S. and the interface between public and private entities responsible for vaccine development and immunization programs.
    • NVPO reorganized during my tenure and I was reassigned to the FDA.
       
    1980 - 1993  

    Various positions (with progression of responsibility), Centers for Disease Control and Prevention (primarily the National Immunization Program and the Division of Viral and Rickettsial Diseases, NCID), Atlanta, GA (1980 - 1993)

    • Served as Epidemic Intelligence Service (EIS) Officer and Supervisory Medical Epidemiologist assigned to various outbreak investigations and special field studies, primarily related to influenza and other vaccine-preventable diseases.
    • Principal investigator or Project Director for several large-scale, controlled field trials and observational research studies of licensed and investigational vaccines, including influenza, polio, pertussis, and measles.
    • Established poliomyelitis eradication activity at CDC to provide WHO and WHO Regional Offices (esp. Americas and Western Pacific) with funding, technical support and training.
    • Architect of flaccid paralysis surveillance system used in the Americas and performance indicators (later adapted by other Regions).
    • Wrote the National Plan of Action for the Eradication of Poliomyelitis in China (target achieved within 2 years).
    HONORS AND AWARDS
    2001   FDA Commissioner's Group Recognition Award (for helping to avert a major influenza vaccine shortage in the U.S.)
    2001   Center for Biologics Evaluation & Research Group Award (for outstanding public health achievement related to risk assessment and public communication regarding the presence of bovine-derived components of vaccines and the potential for vCJD
    2000   U.S. Public Health Service Outstanding Unit Citation (for contributions related to the investigation of intussusception among recipients of live, attenuated rotavirus vaccine)
    1999   Certificate of Commendation, American Academy of Pediatrics ("in recognition of important contributions made to the mission and goals of the Academy and to the children")
    1998   U.S. Public Health Service Distinguished Service Medal (for exemplary contributions related to influenza control and pandemic preparedness in the U.S.; this is the highest award given to a Commissioned Officer)
    1997   FDA Commissioner's Citation and U.S. Public Health Service Unit Commendation (for public health response to a voluntary recall of influenza vaccine)
    1996   Center for Biologics Evaluation & Research Group Award (for outstanding public health achievement related to the safety of substrates used in the production of viral vaccines)
    1995   U.S. Public Health Service Unit Commendation (for contributions related to vaccine safety); Center for Biologics Evaluation & Research Group Award (for outstanding contributions related to policy development for poliovirus vaccines)
    1993   U.S. Public Health Service Unit Commendation (for operational research in support of CDC's Infant Immunization Initiative)
    1991   U.S. Public Health Service Outstanding Service Medal (for contributions related to the poliomyelitis eradication initiative).
    1988   U.S. Public Health Service Medal of Commendation (for contributions related to the prevention and control of pertussis in the U.S.)
    1984   U.S. Public Health Service Medal of Achievement (for contributions related to the prevention and control of influenza infection in nursing homes)
    1982   Co winner, Alexander D. Langmuir Prize for the best manuscript submitted by an EIS Officer ("Risk Factors for Heatstroke: A Case Control Study").
    1976   Alpha Omega Alpha (AOA) Honor Medical Society (Louisiana Alpha Chapter, Tulane University School of Medicine [as 3rd-year medical student]).

    UNIFORMED SERVICES EXPERIENCE
    Aug 2000   Voluntarily retired as Captain (Rank 0-6)
    1980-2000   Served as a Commissioned Officer in the United States Public Health Service

    ACADEMIC ACTIVITIES
    Academic appointments: Department of International Health, Johns Hopkins University School of Hygiene and Public Health (1994-2001) and Emory University School of Public Health (1989-1993).
    Editorial Review for Peer-Reviewed Journals: Journal of Infectious Diseases, Clinical Infectious Diseases, Annals of Internal Medicine, New England Journal of Medicine, Journal of the American Medical Association, Pediatrics.
    PROFESSIONAL SOCIETIES
    • American Society for Microbiology
    • Drug Information Association (DIA)
    • Food & Drug Law Institute (FDLI)
    • Infectious Diseases Society of America (Fellow)
    • Regulatory Affairs Professional Society (RAPS)
    BIBLIOGRAPHY

    1. Treanor JJ, El Sahly H, King J, Graham I, Izikson R, Kohberger R, Patriarca P, Cox M.  Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults:  a randomized, placebo-controlled trial.  Vaccine (in press).
    2. Baxter R, Patriarca PA, Ensor K, Izikson R, Goldenthal KL, Cox MM Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age. Vaccine. 2011 Mar 9;29(12):2272-8. Epub 2011 Jan 28.
    3. Keitel WA; Treanor JJ; El Sahly HM;  Gilbert A; Meyer AL; Patriarca PA; Cox MM.  Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccines (TIV) among persons ≥65 years old.  Submitted for publication, J Infect Dis, February 2009
    4. King JC Jr, Cox MM, Reisinger K, Hedrick J, Graham I, Patriarca P. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months.  Vaccine 2009; 27:6589-94. Epub 2009 Aug 27.
    5. Cox MM, Patriarca PA, Treanor J.  FluBlok, a recombinant hemagglutinin influenza vaccine. Influenza and Oth Resp Vir 2008; 2:201-9.
    6. Patriarca PA.  New options for prevention and control of influenza (editorial).  JAMA 1999;282:75-7.
    7. Gensheimer KF, Fukuda K, Brammer L, Cox NJ, Patriarca PA.  Preparing for pandemic influenza.  The need for enhanced surveillance.  Emerg Infect Dis J 1999;5:297-9.
    8. Braun MM, Terracciano G, Salive ME, Blumberg DA, Vermeer-de Bondt PE, Heijbel H, Evans G. Patriarca PA, Ellenberg SS.   Report of a US Public Health Service workshop on hypotonic-hyporesponsive episodes (HHE) following pertussis immunization.  Pediatrics 1998;102:E52.
    9. Patriarca PA, Cox NJ.  Influenza pandemic preparedness plan for the United States.  J Infect Dis 1997;176(suppl 1):S4-7.
    10. Chen RT, Glasser JW, Rhodes PH, ... and the Vaccine Safety Datalink Team [P. Patriarca].  Vaccine safety datalink project: A tool for improving vaccine safety monitoring in the United States.  Pediatrics 1997;99:765-773.
    11. Braun MM, Patriarca PA, Ellenberg SS.  Syncope after immunization.   Arch Pediatr Adolesc Med 1997;151:255-259.
    12. Patriarca PA, Sutter RW, Oostsvogel P.  Outbreaks of poliomyelitis, 1976-1995.  J Infect Dis 1997;175(Suppl 1):S165-172.
    13. Reichler MR, Abbas A, Kharabsheh S, ... Patriarca PA.  Outbreak of paralytic poliomyelitis in a highly immunized population in Jordan.  J Infect Dis 1997;175(Suppl 1):S62-70.
    14. Reichler MR, Kharabsheh S, Rhodes P, ... Patriarca PA.  Increased immunogenicity of oral poliovirus vaccine administered in mass vaccination campaigns compared with routine vaccination program in Jordan.  J Infect Dis 1997;175(Suppl 1):S198-204.
    15. WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines [PA Patriarca, Project Director, CDC].  Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in The Gambia, Oman, and Thailand.  J Infect Dis 1997;175(Suppl 1):S215-227.
    16. Posey DL, Linkins RW, Couto Oliveria MJC, Monteiro D, Patriarca PA.  Effect of diarrhea on oral poliovirus vaccine failure in Brazil.  J Infect Dis 1997;175 (Suppl 1):S258-263.
    17. Modlin JF, Halsey NA, Thoms ML, Meschievitz C, Patriarca PA.  Serum neutralizing antibody response to three experimental sequential IPV-OPV immunization schedules.  J Infec Dis 1997;175(Suppl 1):S235-240.
    18. WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines [PA Patriarca, Project Director, CDC].  Combined immunization of infants with oral and inactivated poliovirus vaccines.  Bull WHO 1996;74:253-68.
    19. Patriarca PA.  Oral poliomyelitis vaccines [Commentary].  Lancet 1996;347:1495.
    20. Chen RT, Hausinger S, Dajani AS, Hanfling M, Baughman AL, Pallansch MA, Patriarca PA.  Seroprevalence of antibody against poliovirus in inner-city preschool children.  Implications for vaccination policy in the United States.  JAMA 1996;275:1639-45.
    21. Bart KJ, Foulds J, Patriarca PA.  Global eradication of poliomyelitis: benefit-cost analysis.  Bull WHO 1996;74:33-43.
    22. Markowitz LE, Albrecht P, Rhodes P, Demonteverde R, Swint E, Maes EF, Powell C, Patriarca PA.  Changing levels of measles antibody titers in women and children in the United States.  Impact on the response to vaccination.  Pediatrics 1996;97:53-8.
    23. WHO Collaborative Study Group on Oral Poliovirus Vaccines [PA Patriarca, Project Director].  Factors affecting the immunogenicity of oral poliovirus vaccine.  A prospective evaluation in Brazil and The Gambia. J Infect Dis 1995;171:1097-1106.
    24. Patriarca PA, Strikas RA.  Influenza vaccine for healthy adults? [Editorial]  N Engl J Med 1995;333:933-34.
    25. Richardson G, Linkins RW, Eames MA, Wood DJ, Campbell PJ, Ankers E, Deniel M, Kabbaj A, Magrath DI, Minor PD, Patriarca PA.  Immunogenicity of oral poliovirus vaccine administered in mass campaigns versus routine immunization programmes.  Bull WHO 1995;73:769-777.
    26. Linkins RW, Mansour E, Wassif O, Hassan MH, Patriarca PA.  Evaluation of house-to-house versus fixed site oral poliovirus vaccine delivery strategies in a mass immunization campaign in Egypt.  Bull WHO 1995;73:589-95.
    27. Van Loon F, Patriarca PA.  Oral rehydration solution as an adjuvant for oral vaccination.  Lancet 1995;345:580-81.
    28. Patriarca PA, Beeler JA.  Measles vaccination and inflammatory bowel disease [Commentary].  Lancet 1995;345:1062-3.
    29. Patriarca PA.  A randomized controlled trial of influenza vaccine in the elderly: scientific scrutiny and ethical responsibility (Editorial).  JAMA 1994;272:1700-1.
    30. Mullooly JP, Bennett MD, Hornbrook MC, Barker WH, Williams WW, Rhodes P, Patriarca PA.  Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization.  Ann Intern Med 1994;121:947-52.
    31. Patriarca PA.  Polio outbreaks: A tale of torment [Commentary].  Lancet 1994;344:630-31.
    32. Strebel P, Aubert-Combiescu A, Ion-Nedelcu N, Biberi S, Combiescu M, Sutter R, Cochi S, Patriarca PA, Pallansch MA, Kew OM, Chumakov K.  Paralytic poliomyelitis in Romania, 1984-1992: evidence for a high risk of vaccine-associated disease and reintroduction of wild-virus infection.  Amer J Epidemiol 1994;140:1111-24.
    33. Linkins RW, Dini EF, Patriarca PA.  A randomized trial of the effectiveness of computer-generated telephone messages in increasing immunization rates among preschool children.  Arch Pediatr Adolesc Med 1994;148:908-14
    34. Patriarca PA, Foege WH, Swartz TA.  Progress in polio eradication.  Lancet 1993;342:1461-4
    35. Patriarca PA.  Poliomyelitis in selected African and Asian countries.  Public Health Rev 1993/94;21:91-8
    36. Patriarca PA.  Global eradication of poliomyelitis.  Summary of a symposium.  Public Health Rev 1993/94;21:161-4
    37. Patriarca PA, Linkins RW, Sutter RW.  Poliovirus vaccine formulations.  In: Kurstak E (ed.): Measles and Poliomyelitis: Vaccines and Immunization.  New York, Springer-Verlag, 1993; 242-51.
    38. Patriarca PA, Linkins RW, Sutter RW, Orenstein WA.  Optimal schedule for the administration of oral poliovirus vaccine.  In: Kurstak E (ed.): Measles and Poliomyelitis: Vaccines and Immunization.  New York, Springer-Verlag, 1993, pp.303-13.
    39. Sutter RW, Cochi SL, Patriarca PA.  Epidemiologic and laboratory classification systems for paralytic poliomyelitis cases.  In: Kurstak E (ed.): Measles and Poliomyelitis: Vaccines and Immunization.  New York, Springer-Verlag, 1993, pp.235-47.
    40. Sutter RW, Patriarca PA.  Inactivated and live attenuated poliovirus vaccines.  Mucosal immunity.  In: Kurstak E (ed.): Measles and Poliomyelitis: Vaccines and Immunization.  New York, Springer-Verlag, 1993, pp.279-94.
    41. Sutter RW, Patriarca PA, Suleiman AJM, et al.  Paralytic poliomyelitis in Oman.  Association between regional differences in attack rate and variations in antibody responses to oral poliovirus vaccine.  Int J Epidemiol 1993;22:936-44.
    42. Stehr-Green PA, Dini EF, Lindegren ML, Patriarca PA.  Evaluation of the impact of computer-generated telephone reminders on on-time immunization in inner-city clinics.  Public Health Rep 1993;108:426-30.
    43. Moriniere BM, Van Loon FPL, Rhodes PH, Klein-Zabban ML, Frank-Sennat B, Herrington JE, Pallansch MA, Patriarca PA.  Serologic responses following a supplemental dose of oral vs. inactivated poliovirus vaccine.  Lancet 1993;341:1545-50.
    44. Farizo KM, Cochi SL, Zell ER, Brink EW, Wassilak SG, Patriarca PA.  Epidemiologic features of pertussis in the United States, 1980-1989.  Clin Infect Dis 1992;14:708-719.
    45. Farizo KM, Stehr-Green PA, Markowitz LE, Patriarca PA.  Immunization levels and missed opportunities for measles vaccination.  A record audit in a public pediatric clinic.  Pediatrics 1992;89:589-592.
    46. Sutter RW, Patriarca PA, Suleiman AJM, et al.  Attributable risk of DTP injection in provoking paralytic poliomyelitis during a large outbreak in Oman.  J Infect Dis 1992;165:444-449.
    47. Sprauer MA, Cochi SL, Zell ER, Sutter RW, Mullen JR, Englander SJ, Patriarca PA.  Prevention of secondary transmission of pertussis in households with early use of erythromycin.  Am J Dis Child 1992;146:177-181.
    48. King GE, Markowitz LE, Patriarca PA, Dales LG.  Clinical efficacy of measles vaccine during the 1990 measles epidemic.  Pediatr Infect Dis J 1991;10:883-887.
    49. Patriarca PA, Wright PF, John TJ.  Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries.  A  review.  Rev Infect Dis 1991;13:926-39.
    50. Patriarca PA, Sutter RW.  Poliomyelitis.  In: Last JM (ed.): Maxcy-Rosenau Public Health and Preventive Medicine (13th Edition).  East Norwalk, CT, Appleton-Century-Crofts, 1991:80-81.
    51. Sutter RW, Patriarca PA, Brogan S, Malankar PG, Pallansch MA, Kew OM, Bass AG, Cochi SL, Alexander J, Mohammed AJ, El-Bualy M.  Outbreak of paralytic poliomyelitis in Oman: Evidence for transmission among fully vaccinated children.  Lancet 1991;338:715-20.
    52. Cutts FT, Henderson RH, Clements CJ, Chen RT, Patriarca PA.  Principles of measles control.  Bull WHO 1991;69:1-7.
    53. Sutter RW, Onorato IM, Patriarca PA.  Current poliomyelitis immunization policy in the United States.  Pediatr Ann 1990;19:702-6.
    54. Farizo KM, Cochi SL, Patriarca PA.  Poliomyelitis in the United States.  An historical perspective and current vaccination policy.  J Amer Coll Health Assoc 1990;32:137-43.
    55. Patriarca PA.  Clinical experiences with acute hemorrhagic conjunctivitis in the United States.  In: Ishii K (ed.)  Acute hemorrhagic conjunctivitis.  Tokyo, University of Tokyo 1989, pp.285-9.
    56. Hutchins SS, Cochi SL, Brink EW, Patriarca PA, Wassilak SGF, Rovira EZ, Hinman AR.  Current epidemiology of pertussis in the United States.  Tokai J Exp Clin Med 1988;13(suppl):103-110.
    57. Patriarca PA, Steketee RW, Biellik RJ, Wassilak SGF, Brink EW, Burstyn DG, Manclark CW, Davis JP.  Outbreaks of pertussis in the United States.  The Wisconsin experience.  Tokai J Exp Clin Med 1988;13(suppl):117-124.
    58. Patriarca PA, Laender F, Palmeira G, et al.  A randomized trial of alternative formulations of oral polio vaccine in Brazil.  Lancet 1988;i:429-33.
    59. Patriarca PA, Biellik RJ, Sanden G, et al.  Sensitivity and specificity of clinical case definitions for pertussis.  Am J Public Health 1988;78:833-6.
    60. Biellik RJ, Patriarca PA, Rovira EZ, et al.  Risk factors for community- and household-acquired pertussis during a large-scale outbreak in central Wisconsin.  J Infect Dis 1988;157:1134-41.
    61. Arden NH, Patriarca PA, Fasano MB, et al.  Roles of vaccination and chemoprophylaxis in controlling an outbreak of influenza A (H3N2) in a nursing home.  Arch Intern Med 1988;148:865-8.
    62. Slepushkin AN, Patriarca PA, Obrosova-Serova N, et al.  Class-specific antibody responses in school children vaccinated with an A/Brazil/11/78 (H1N1)-like recombinant influenza virus prepared from the A/Leningrad/134/57 pediatric cold-adapted donor strain.  Vaccine 1988;6:25-8.
    63. Hinman AR, Foege WH, de Quadros CA, Patriarca PA, Orenstein WA, Brink EW. The case for global eradication of poliomyelitis.  Bull WHO 1987;65:835-40.
    64. Patriarca PA, Arden NH, Koplan JP, Goodman RA.  Prevention and control of type A influenza in nursing homes.  Benefits and costs of four approached using vaccination and amantadine.  Ann Intern Med 1987;107:732-40.
    65. Hutchins SS, Patriarca PA, Wassilak SGF, et al.  Pertussis in the United States, 1979-85.  In: Proceedings of the 21st Annual Immunization Conference. Atlanta: Centers for Disease Control.  U.S. Department of Health and Human Services, Public Health Service, 1987:35-42.
    66. Patriarca PA, Wassilak SGF, Onorato IM, et al.  Reporting criteria for pertussis.  In: Proceedings of the 21st Annual Immunization Conference. Atlanta: Centers for Disease Control.  U.S. Department of Health and Human Services, Public Health Service, 1987:43-6.
    67. Patriarca PA.  Optimal timing for influenza vaccination (Question & Answer Section).  JAMA 1987;258:964.
    68. Patriarca PA, Weber JA, Parker RA, et al.  Risk factors for outbreaks of influenza in nursing homes.  A case-control study.  Am J Epidemiol 1986;124:114-9.
    69. Atkinson WL, Arden NH, Patriarca PA, et al.  Amantadine prophylaxis during an institutional outbreak of type A (H1N1) influenza.  Arch Intern Med 1986;146:1751-6.
    70. Arden NH, Patriarca PA, Harmon MW, Lui K, Brandon F, Kendal AP.  Safety and immunogenicity of a 45-ug supplemental dose of inactivated split-virus influenza B vaccine in the elderly.  J Infect Dis 1986;153:805-6.
    71. Patriarca PA, Brink EW, Orenstein WA, Bernier R, Hinman AR.  Efficacy of acellular pertussis vaccine [Letter].  J Pediatr 1986;108:632-3.
    72. Kendal AP, Patriarca PA (eds).  Options for the Control of Influenza.  New York, Alan R. Liss, 1986, 586 pages.
    73. Arden NH, Patriarca PA, Kendal AP.  Experiences in the use and efficacy of influenza vaccine in nursing homes.  In Kendal AP, Patriarca PA (eds.)  Options for the Control of Influenza.  New York, Alan R. Liss, 1986:155-68.
    74. Kendal AP, Arden NH, Patriarca PA.  Influenza: New strategy against an old enemy.  In: de la Maza LM, Peterson M (eds).  Medical Virology IV.  Hillsdale, NJ, Lawrence Erlbum Associates, Inc., 1986:377-408.
    75. Dull HB, Kendal AP, Patriarca PA.  Influenza. In Last JM (ed): Maxcy-Rosenau Public Health and Preventive Medicine.  East Norwalk, CT, Appleton-Century-Crofts, 1986, pp. 129-147.
    76. Kendal AP, Patriarca PA, Arden NH.  Policies and outcomes for control of influenza among the elderly in the U.S.A.  Vaccine 1985;3(suppl):274-6.
    77. Patriarca PA, Kendal AP, Weber JA, Hall WN.  Efficacy of influenza vaccine [letter].  JAMA 1985;254:1451-2.
    78. Patriarca PA, Weber JA, Meissner MA, et al.  Use of influenza vaccine in nursing homes.  J Amer Geriatr Soc 1985;33:463-6.
    79. Patriarca PA, Arden NH.  Influenza vaccine: the vicious cycle begins to break.  In: Proceedings of the 20th Annual Immunization Conference. Atlanta: Centers for Disease Control.  U.S. Department of Health and Human Services, Public Health Service, 1985:33-5.
    80. Langford MP, Barber JC, Sklar VEF, Clark SW, Patriarca PA, Onorato IM, Yin-Murphy M, Stanton GJ.  Virus specific, early appearing neutralizing activity and interferon in tears of patients with acute hemorrhagic conjunctivitis.  Curr Eye Res 1985;4:233-9.
    81. Patriarca PA, Weber JA, Parker RA, et al.  Efficacy of influenza vaccine in nursing homes.  Reduction in illness and complications during an influenza A (H3N2) epidemic.  JAMA 1985;253:1136-9.
    82. Patriarca PA, Kater NA, Kendal AP, Bregman DJ, Smith JD, Sikes RK.  Safety of prolonged administration of rimantadine hydrochloride in the prophylaxis of influenza A infections in nursing homes.  Antimicrob Agents Chemother 1984;26:101-3.
    83. Goodman RA, Patriarca PA.  Influenza in hospitalized patients.  Asepsis 1984;6:5-8.
    84. Patriarca PA, Kendal AP, Zakowski PC, et al.  Lack of significant person-to-person spread of swine influenza-like virus following fatal infection in an immunocompromised child.  Am J Epidemiol 1984;119:152-8.
    85. Patriarca PA.  Influenza vaccination: Breaking the vicious cycle.  In: Proceedings of the 18th Annual Immunization Conference. Atlanta: Centers for Disease Control.  U.S. Department of Health and Human Services, Public Health Service, 1983:175-7.
    86. Kuritsky JN, Weaver JH, Bernard KW, Mokhbat JE, Hatch MH, Osterholm MT, Patriarca PA.  An outbreak of acute hemorrhagic conjunctivitis in central Minnesota.  Am J Ophthalmol 1983;96:449-52.
    87. Anderson LJ, Patriarca PA, Hierholzer JC, Noble GR.  Viral respiratory illnesses.  Med Clinics N Amer 1983;67:1009-30.
    88. Patriarca PA, Kendal AP, Stricof RL, Weber JA, Meissner MK, Dateno B.  Influenza vaccination and warfarin or theophylline toxicity in nursing home residents.  N Engl J Med 1983;308:1601-2.
    89. Patriarca PA, Onorato IM, Sklar VEF, et al.  Acute hemorrhagic conjunctivitis. Investigation of a large-scale community outbreak in Dade County, Florida.  JAMA 1983;249:1283-9.
    90. Sklar VEF, Patriarca PA, Onorato IM, et al.  Clinical findings and results of treatment in an outbreak of acute hemorrhagic conjunctivitis in southern Florida.  Am J Ophthalmol 1983;95:45-54.
    91. Patriarca PA, Rogers MF, Morens DM, et al.  Kawasaki syndrome: association with the application of rug shampoo.  Lancet 1982;2:578-80.
    92. Patriarca PA, Schlech WF, Hinman AR, Conn JM, Gunn WJ.  Pneumococcal vaccination practices among private physicians.  Public Health Rep 1982;97:406-8.
    93. Nolan TF, Goodman RA, Patriarca PA, Hinman AR.  Hospitalizations for measles, 1970-1978.  Am J Public Health 1982;72:1037-9.
    94. Kilbourne EM, Choi K, Jones TS, et al.  Risk factors for heatstroke: a case-control study.  JAMA 1982;247:3332-6.
    95. Jones TS, Liang AP, Kilbourne EM, et al.  Morbidity and mortality associated with the July 1980 heat wave in St. Louis and Kansas City, Missouri.  JAMA 1982;247:3327-31.
    96. Patriarca PA, Morens DM.  Aneurysms in Kawasaki disease.  J Pediatr 1982;100:509-10.
    97. Patriarca PA.  Pneumococcal vaccine update.  In: Proceedings of the 16th Annual Immunization Conference, May 1981.  Atlanta: Centers for Disease Control.  U.S. Department of Health and Human Services, Public Health Service, 1981.
    98. Patriarca PA, Nolan TF, Bernier RF, Hinman AR.  Advances in antiviral chemotherapy: amantadine and influenza.  Med J Aust 1980;2:631-2.
    99. Patriarca PA, Lauer BA.  Ventriculoperitoneal shunt-associated infection due to Haemophilus influenzae.  Pediatrics 1980;65:1007-9.

    Page Updated: August 19, 2011

Copyright © 2010  Biologics Consulting Group, Inc. - All Rights Reserved